Bilthoven Biologicals Netherlands Scales Up Production To Meet Critical Global Vaccine Shortages

BILTHOVEN, Netherlands — As global healthcare systems face mounting pressure to secure critical pharmaceutical supply chains, Bilthoven Biologicals (BBio) in the Netherlands has solidified its position as a cornerstone of international immunization and biodefense efforts in 2026. Owned by the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, the Dutch facility is accelerating operations to address worldwide shortages of Inactivated Polio Vaccines (IPV) and crucial bladder cancer therapeutics.

Context & Background

Acquired by the Serum Institute of India in 2012, Bilthoven Biologicals transitioned from a state-run Dutch vaccine institute into a highly specialized commercial powerhouse. Situated at the Utrecht Science Park Bilthoven, the facility provides the Serum Institute with a crucial manufacturing footprint inside the European Union. This geographic advantage allows BBio to align its high-standard manufacturing capabilities directly with European Medicines Agency (EMA) and World Health Organization (WHO) regulatory frameworks.

For over a decade, BBio’s primary mandate has been supporting the Global Polio Eradication Initiative (GPEI). The facility is one of the few sites globally equipped with the biosafety infrastructure required to produce IPV using wild-type polio strains. Following years of infrastructure optimization under SII's leadership, the facility now processes millions of doses annually, serving as a vital supplier to UNICEF and Gavi, the Vaccine Alliance.

Impact & Utility

The strategic value of Bilthoven Biologicals in 2026 extends far beyond polio eradication. The facility plays an indispensable role in two major areas of global health security:

• Oncology Support (BCG Vaccine): BBio is one of the principal global suppliers of the Bacillus Calmette-Guérin (BCG) vaccine, used not only for tuberculosis prevention but also as a primary immunotherapeutic treatment for non-muscle invasive bladder cancer. Persistent global shortages of BCG have made BBio’s production lines critical for oncology departments worldwide.
• European Pandemic Preparedness: Through strategic partnerships, including collaborative frameworks with the Coalition for Epidemic Preparedness Innovations (CEPI), BBio acts as a rapid-response manufacturing hub. In the event of a localized pathogen outbreak in Europe, the facility can pivot to scale up candidate vaccines, reducing the continent's reliance on external supply chains.

The integration of SII’s massive distribution network with BBio’s European-based manufacturing standards ensures that high-quality biologicals are distributed efficiently to both high-income countries and low-to-middle-income countries (LMICs).

What's Next

As the global healthcare community targets the final phases of polio eradication, Bilthoven Biologicals is undergoing a phased modernization program. Moving into late 2026 and 2027, the facility is focusing on:

1. Digitalization and Automation: Implementing advanced AI-driven monitoring systems to optimize bioreactor yields and reduce batch failure rates.
2. Decarbonization Goals: Aligning with the European Green Deal by upgrading its Utrecht facilities to meet strict net-zero manufacturing standards.
3. Product Diversification: Exploring tech-transfer initiatives with the Serum Institute of India to manufacture next-generation recombinant vaccines and monoclonal antibodies.

With vaccine sovereignty remaining a top political and economic priority for the European Union, Bilthoven Biologicals is poised to secure further public-private funding to ensure Europe retains its competitive edge in biotechnology.